当前位置: X-MOL 学术Int. J. Impot. Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Effects of oral phentolamine, taken before sleep, on nocturnal erectile activity: a double-blind, placebo-controlled, crossover study.
International Journal of Impotence Research ( IF 2.6 ) Pub Date : 2002-03-14 , DOI: 10.1038/sj.ijir.3900731
D G Hatzichristou 1 , A Apostolidis , V Tzortzis , K Hatzimouratidis , D Kouvelas
Affiliation  

The objective of this study was to determine the effects of oral phentolamine, administered before sleep, on nocturnal penile erectile activity of men with mild to moderate erectile dysfunction (ED). We studied five patients with mild to moderate ED (mean age 34.8 +/- 8.13 and mean duration of ED 31.8 +/- 23.5 months), in a double-blind, placebo-controlled, crossover study. All patients received oral phentolamine (Vasomax) at a dose of 40 mg and placebo for three consecutive nights respectively and were submitted to nocturnal penile tumescence and rigidity monitoring (NPTR) with the Rigiscan device. NPTR parameters of the two 3-night recordings were evaluated and compared. Administration of oral phentolamine before sleep was associated with a statistically significant increase in the number of erectile events with rigidity > or = 60% lasting > or = 10 min (P = 0.02), as well as the rigidity activity units (RAU) value per hour sleep, both at the base (P = 0.023) and the tip of the penis (P = 0.019). The number of events as measured by Rigiscan software (20% change in circumference), as well as tumescence activity units (TAU)/h values did not show any statistical difference. No adverse effects were recorded. It is concluded that oral phentolamine administered before sleep enhanced NPTR parameters associated with the quality of the erectile events. Such results provide a pathway for the development of a prevention strategy for ED. Future studies will elucidate whether vasoactive agents taken on a regular basis before sleep, can prevent ED in men at risk, protecting also minimally and moderately impotent patients to become moderately and severely impotent respectively.

中文翻译:

睡眠前口服酚妥拉明对夜间勃起活动的影响:一项双盲,安慰剂对照,交叉研究。

这项研究的目的是确定睡眠前口服酚妥拉明对轻度至中度勃起功能障碍(ED)男性夜间阴茎勃起活性的影响。在一项双盲,安慰剂对照,交叉研究中,我们研究了5例轻至中度ED(平均年龄34.8 +/- 8.13,平均ED持续时间31.8 +/- 23.5个月)的患者。所有患者分别连续三个晚上接受了口服苯妥拉明(Vasomax)的剂量40 mg和安慰剂治疗,连续三个晚上,并通过Rigiscan设备进行了夜间阴茎勃起和刚度监测(NPTR)。评估并比较了两个3晚录制的NPTR参数。睡眠前口服酚妥拉明与僵硬>的勃起事件数量有统计学意义的增加 或= 60%持续性>或= 10分钟(P = 0.02),以及每小时睡眠的刚度活动单位(RAU)值,无论是在底部(P = 0.023)还是在阴茎尖端(P = 0.019) )。用Rigiscan软件测量的事件数(周长变化20%)以及肿胀活动单位(TAU)/ h值均未显示任何统计学差异。没有不良反应的记录。结论是,睡眠前口服酚妥拉明可增强与勃起事件质量相关的NPTR参数。这样的结果为制定ED的预防策略提供了途径。未来的研究将阐明在睡前定期服用血管活性剂是否可以预防高危男性的ED,同时还可以保护轻度和中度无力的患者分别变为中度和重度的无力。
更新日期:2019-11-01
down
wechat
bug